Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I

Wahezi, DM; Nt, Ilowite; Wu, Xiaoyun; Pelkmans, Leonie; Laat, Bas de; Schanberg, LE; Rand, JH

doi:10.1177/0961203313490241

Cited by 23 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wahezi et al reported a prevalence of IgG anti-DI of 25.1% in children with SLE. However, only seven children had thrombosis, failing to ascertain a positive correlation 20 . In a study on 64 APS patients and 57 children born to mothers with systemic autoimmune diseases, Andreoli et al s howed a high prevalence of anti-DI in APS while there was a low anti-DI frequency reported in anti-β2GPI positive healthy children 21 .…”

Section: New Apl Specificitiesmentioning

confidence: 91%

Recent advances in understanding antiphospholipid syndrome

Bertolaccini

Sanna

2016

F1000Res

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS), also known as Hughes Syndrome, is a systemic autoimmune disease characterized by thrombosis and/or pregnancy morbidity in the presence of persistently positive antiphospholipid antibodies. A patient with APS must meet at least one of two clinical criteria (vascular thrombosis or complications of pregnancy) and at least one of two laboratory criteria including the persistent presence of lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and/or anti-b2 glycoprotein I (anti-b2GPI) antibodies of IgG or IgM isotype at medium to high titres in patient’s plasma. However, several other autoantibodies targeting other coagulation cascade proteins (i.e. prothrombin) or their complex with phospholipids (i.e. phosphatidylserine/prothrombin complex), or to some domains of β2GPI, have been proposed to be also relevant to APS. In fact, the value of testing for new aPL specificities in the identification of APS in thrombosis and/or pregnancy morbidity patients is currently being investigated.

show abstract

Section: New Apl Specificitiesmentioning

confidence: 91%

Recent advances in understanding antiphospholipid syndrome

Bertolaccini

Sanna

2016

F1000Res

View full text Add to dashboard Cite

show abstract

“…Furthermore, children with SLE and positive anti-DI antibodies had significantly lower mean annexin A5 resistance levels compared to those with negative anti-DI antibodies. In multivariate analysis, anti-DI antibodies and LA were both independently associated with reduced annexin A5 resistance [52].…”

Section: Anti-domain I Antibodies In Systemic Lupus Erythematosusmentioning

confidence: 94%

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

Chighizola¹,

Borghi²,

Grossi³

et al. 2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid antibodies (aPL), the serological markers of antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by vascular thrombosis and/or pregnancy morbidity. aPL are detected in 20 to 50% of patients with systemic lupus erythematosus (SLE), representing a poor prognostic factor. Indeed, thrombotic events heralds high morbidity and mortality, being regarded as the strongest predictors of death in the first five years after SLE onset. It would be thus very important to identify a reliable laboratory tool such as anti-domain antibodies to better risk-stratify lupus patients according to the aPL profile, in order to tailor treatment strategies. Domain I (DI) of β 2 GPI has lately been identified as the main epitope targeted by antibodies reacting against β 2 GPI isolated from APS patients, well correlating with thrombotic as well as obstetric manifestations. Interestingly, anti-DI antibodies have been shown to well correlate with lupus anticoagulant and to predict the clinical manifestations of the syndrome, thrombotic events as well as pregnancy complications. Further, anti-DI antibodies allow to identify patients at highest clinical risk, presenting a good specificity for APS. On the other hand, anti-β 2 GPI antibodies from aPL asymptomatic carriers or subjects with infectious diseases preferentially display reactivity towards DIV or DV of the molecule.Few studies have to date evaluated the domain profile of anti-β 2 GPI antibodies in subjects with SLE, even though it would be very relevant from a clinical point of view to understand whether among patients with SLE the domain specificities of anti-β 2 GPI antibodies display a clinical meaning comparable to the one they exert in APS. It is therefore rather appropriate to review the available evidence about anti-domain specificities with a particular focus on SLE.

show abstract

“…A reduction of annexin A5 anticoagulant activity is correlated with SLE pathogenesis in children [89]. Annexin A5 binds anionic phospholipids and blocks coagulation enzymatic reactions [90].…”

Section: 0 the Role Of Coagulation Evasion In Diseasementioning

confidence: 99%

“…In addition, aPL Ab can interfere with annexin A5 binding to phospholipids and promote thrombosis events in APLS patients. This is influenced by an increased level of anti-domain 1 Ab to beta-2-glycoprotein I, which are found in children and adolescents with SLE [89] and significantly increase the risk of thrombosis [91]. …”

Section: 0 the Role Of Coagulation Evasion In Diseasementioning

confidence: 99%

Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer

Rettig

Harbin

Harrington

et al. 2015

Clinical Immunology

View full text Add to dashboard Cite

The humoral innate immune system is composed of three major branches, complement, coagulation, and natural antibodies. To persist in the host, pathogens, such as bacteria, viruses, and cancers must evade parts of the innate humoral immune system. Disruptions in the humoral innate immune system also play a role in the development of autoimmune diseases. This review will examine how gram positive bacteria, viruses, cancer, and the autoimmune conditions Systemic Lupus Erythematosus and Anti-phospholipid syndrome, interact with these immune system components. Through examining evasion techniques it becomes clear that interplay between these three systems exists. By exploring the interplay and the evasion/disruption of the humoral innate immune system, we can develop a better understanding of pathogenic infections, cancer, and autoimmune disease development.

show abstract

Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I

Cited by 23 publications

References 29 publications

Recent advances in understanding antiphospholipid syndrome

Recent advances in understanding antiphospholipid syndrome

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer

Contact Info

Product

Resources

About